{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:32:48Z","timestamp":1775277168584,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.kint.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:30:24Z","timestamp":1732095024000},"page":"1015-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Has APOL1 kidney disease treatment been hiding in plain sight?"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-7605","authenticated-orcid":false,"given":"Opeyemi A.","family":"Olabisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.kint.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMc1800748","article-title":"Worldwide frequencies of APOL1 renal risk\u00a0variants","volume":"379","author":"Nadkarni","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.003_bib4","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048952","article-title":"Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease","volume":"14","author":"McCarthy","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.kint.2024.09.003_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172262","article-title":"APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease","volume":"134","author":"Datta","year":"2024","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ekir.2024.06.033","article-title":"Design and rationale of the phase 2 baricitinib study in apolipoprotein L1-mediated kidney disease (JUSTICE)","volume":"9","author":"Olabisi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.kint.2024.07.026","article-title":"Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2","volume":"106","author":"Sula Karreci","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.mayocp.2020.12.038","article-title":"Barriers to ACEI\/ARB use in proteinuric chronic kidney disease: an observational study","volume":"96","author":"McCoy","year":"2021","journal-title":"Mayo Clin Proc"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824006434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824006434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T20:56:24Z","timestamp":1735332984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824006434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0085253824006434"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.003","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Has APOL1 kidney disease treatment been hiding in plain sight?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.07.026","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}